Human growth hormone peptide 1?43: Isolation from pituitary glands

1983 ◽  
Vol 2 (6) ◽  
pp. 425-436 ◽  
Author(s):  
Rama N. P. Singh ◽  
Boyd K. Seavey ◽  
Loraine J. Lewis ◽  
Urban J. Lewis
1988 ◽  
Vol 4 (4) ◽  
pp. 629-633 ◽  
Author(s):  
Kerstin Albertsson-Wikland ◽  
Agne Larsson

Human growth hormone (GH) has until recently been prepared commercially from pituitary glands collected at autopsy. Availability has been limited and cost high, so the indications for GH treatment have had to be “tight.” Owing to recent development in hybrid DNA technology, the availability of GH has increased dramatically. At the same time, the manufacturers have maintained constant prices, so that treatment costs continue to influence decision making about its use. This rapid transition has generated an interesting change of strategy, which is outlined in this review.


1960 ◽  
Vol 104 (2) ◽  
pp. 232-235 ◽  
Author(s):  
A. Leznoff ◽  
J. Fishman ◽  
L. Goodfriend ◽  
E. McGarry ◽  
J. Beck ◽  
...  

1962 ◽  
Vol 40 (2) ◽  
pp. 311-320 ◽  
Author(s):  
Zvi Laron ◽  
Sara Assa

ABSTRACT Human growth hormone (HGH) prepared from human pituitary glands by the method of Raben (1959) showed two components on agar gel electrophoresis. Fraction I corresponded to a slow alpha-globulin, and fraction II had a mobility between alpha and beta-globulin. On agar gel immunoelectrophoresis using HGH and rabbit antiserum to HGH, these two components showed immunological identity. By using agar gel immunoelectrophoresis and the haemagglutination technique HGH preparations of both Raben and Li type were shown to be contaminated with human albumin. Antiserum to human growth hormone containing also antibodies against human albumin was purified by adsorption with human albumin. It is postulated that part of the difficulties encountered in the use of the haemagglutination-inhibition technique to determine growth hormone concentration in serum, is due to impurities in the human growth hormone preparations and antisera to these preparations in use.


1988 ◽  
Vol 119 (4) ◽  
pp. 501-505
Author(s):  
G. Weber ◽  
Ph. U. Heitz

Abstract. Twelve pituitary glands from patients suffering from psoriasis obtained at postmortem showed in all cases hyperplasia of human growth hormone-producing cells. These results support the postulated pathomechanism that psoriasis lesions may arise as a result of an increased production of human growth hormone.


2020 ◽  
Vol 6 (2) ◽  
pp. 41-49
Author(s):  
R. P. Koirala ◽  
B. Thapa ◽  
S. P. Khanal ◽  
R. P. Adhikari ◽  
N. P. Adhikari

Human growth hormone (hGH) is synthesized, stored and secreted by somatotropic cells within the lateral wings of the anterior lobe of pituitary glands; and is transported to other organs of human body. Study of intra-molecular structure and its binding mechanisms within the molecule gives more insight of structural stability of the molecule and is also essential in drug designing. In this article, we have investigated the various bonded and non-bonded interactions that contribute for the conformation of entire structure of the hGH molecule using molecular dynamics (MD) simulation. The MD outcomes show that the molecule is hydrophobic in nature. In its conformation, several types of interactions exist, such as disulphide bridges (bonded) and nonbonded: hydrogen bond, hydrophobic, aromatic-aromatic, ionic, aromatic-sulphur, cation-pi.


1989 ◽  
Vol 27 (25) ◽  
pp. 97-98

Short stature was first treated in 1958 with growth hormone (GH) made from human pituitary glands.1 In 1985 biosynthetic GH was introduced after several young adults treated with GH in childhood had died from Creutzfeldt-Jakob disease.2 The first biosynthetic GH somatrem (Somatonorm - KabiVitrum) contains an additional methionyl residue and is licensed for treating short stature of Turner’s syndrome as well as GH deficiency. A preparation identical to human GH is now available (somatropin (rbe); Genotropin - KabiVitrum). Who should have it?


1968 ◽  
Vol 58 (2) ◽  
pp. 318-338 ◽  
Author(s):  
N. Norman ◽  
Aa. R. Turter

ABSTRACT A description is given of a radioimmunoassay procedure for human growth hormone (HGH). Particular emphasis is placed on problems encountered with aggregation and unspecific serum protein binding of the 125I radioiodinated HGH. Immunization of rabbits and guinea pigs with a highly purified lipid mobilizing factor (LMF) from human pituitary glands was attempted. This did not result in antibody formation towards LMF, but gave high titers against HGH. The observation thus suggests that LMF may have structural features in common with the HGH molecule. The antibody towards HGH may, however, also have been produced by a minimal contamination with HGH in the LMF. It was shown that detectable antibody formation towards HGH could be produced in rabbits with as little as 5 μg HGH. During the study of two highly purified HGH preparations – the one containing only growth promoting or somatotrophic activity, the other had adipokinetic activity as well - it was shown that the employed radioimmunoassay is specifically directed against the growth promoting part of HGH. Changes in the serum concentration of a possible physiologically acting LMF could therefore not be recorded, neither by a direct assay nor indirectly. On the other hand, the specificity of the HGH assay towards the »somatotrophin proper« assures that it is indeed this hormone that varies in concentration in response to insulin hypoglycaemia, exercise and postprandially. The stress of acute cardiac infarction did not increase growth hormone in the blood.


1979 ◽  
Vol 82 (1) ◽  
pp. 77-86 ◽  
Author(s):  
R. LUMLEY JONES ◽  
G. BENKER ◽  
P. R. SALACINSKI ◽  
T. J. LLOYD ◽  
P. J. LOWRY

SUMMARY A method is described for the large-scale isolation of highly purified human growth hormone for therapeutic use. The hormone was extracted from frozen pituitary glands under mildly alkaline conditions. Purification was effected by gel filtration and ion-exchange chromatography. The final product was pyrogen-free and had a potency of 2·5 i.u./mg measured by bioassay against the current international standard. The yield of growth hormone/gland was approximately 5 mg.


Sign in / Sign up

Export Citation Format

Share Document